We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IQ:NASDAQiQIYI, Inc. Analysis

Data as of 2026-07-24 - not real-time

$1.21

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

iQIYI trades at roughly $1.21, well below its DCF-derived fair value and the consensus analyst targets of $1.41‑$1.54, indicating a sizable upside potential. Technical indicators show a bullish MACD crossover and an RSI of 59, suggesting modest momentum, while the price sits above the identified support of $0.95 but below resistance at $1.27, leaving room for a near‑term rally. Fundamentally, the company is challenged by a 13.4% revenue decline, negative operating and profit margins, and a high debt‑to‑equity ratio exceeding 100%, which dampens confidence in sustainable earnings recovery. The balance sheet is thin, with cash covering only a fraction of total debt, and free cash flow, although positive, is driven by non‑operational items. Recent leadership changes hint at a strategic reset, but the high volatility (≈54% 30‑day) and decreasing volume underscore market uncertainty. Overall, the stock appears deeply discounted relative to its long‑term valuation metrics, yet the combination of weak profitability, regulatory exposure in China, and leverage elevates risk, making a cautious, phased approach advisable.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bullish MACD but neutral price trend
  • Decreasing volume and high short‑term volatility
  • Negative earnings and operating margins

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Significant upside to analyst price targets
  • DCF fair value suggests deep discount
  • Potential operational turnaround under new leadership

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Structural growth opportunity in Chinese streaming
  • Elevated regulatory and debt risks
  • Uncertain path to sustainable profitability

Key Metrics & Analysis

Financial Health

Revenue Growth-13.40%
Profit Margin-2.59%
P/E Ratio14.6
ROE-5.13%
ROA-0.46%
Debt/Equity109.20
P/B Ratio0.6
Op. Cash Flow$-46701000
Free Cash Flow$12.7B
Industry P/E15.3

Technical Analysis

TrendNeutral
RSI59.2
Support$0.95
Resistance$1.27
MA 20$1.11
MA 50$1.10
MA 200$1.63
MACDBullish
VolumeDecreasing
Fear & Greed Index87.88

Valuation

Fair Value$157.45
Target Price$1.55
Upside/Downside27.71%
GradeUndervalued
TypeValue

Risk Assessment

Beta1.21
Volatility54.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.